Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.
A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.
Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.
Rhode Island-based MindImmune Therapeutics forged a research agreement with Pfizer to develop treatments for a number of CNS disorders.
Shares of Voyager Therapeutics fell more than 12 percent in premarket trading after the company announced Sanofi Genzyme walked away from its $845 million gene therapy treatment for Parkinson’s disease.